Investigational drug · Phase 3
Neridronate
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Complex Regional Pain Syndrome Type I.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "Neridronate"
First trial start
2026
Apr 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Neridronate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Complex Regional Pain Syndrome Type I
Approved drugs for the same conditions: Rare and genetic disease · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "Neridronate" as an intervention, largest first.
- Safety of Intravenous Neridronic Acid in CRPSPivotal-lookingCompleted
Grünenthal GmbHIndustry
NCT02972359 · 580 participants · Start Dec 20, 2016 · Primary completion Jan 9, 2019
Drug: Neridronic acid · For: Complex Regional Pain Syndrome
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 46 sites in all
- Efficacy and Safety of Intravenous Neridronic Acid in CRPS-IPivotal-lookingCompleted
Grünenthal GmbHIndustry
NCT02402530 · 459 participants · Start Apr 2015 · Primary completion Aug 2016
Drug: Placebo; Neridronic acid 62.5 mg · For: Complex Regional Pain Syndrome, Type I
Sites: Foley, Alabama; Scottsdale, Arizona; Tucson, Arizona · 59 sites in all
- Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)Pivotal-lookingRecruiting
Ambros Therapeutics, Inc.Industry
NCT07210515 · 270 participants (planned) · Start Apr 14, 2026 · Primary completion Dec 2027
Drug: Neridronate; Placebo · For: Complex Regional Pain Syndrome Type I
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 36 sites in all
- Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)Pivotal-lookingTerminated
Grünenthal GmbHIndustry
NCT03560986 · 267 participants · Start May 31, 2018 · Primary completion Aug 1, 2019
Drug: Neridronic acid 100 mg; Placebo · For: Complex Regional Pain Syndrome (CRPS)
Sites: Cottonwood, Arizona; Tempe, Arizona; Tucson, Arizona · 71 sites in all
- Efficacy and Safety of Intravenous Neridronic Acid in CRPSPivotal-lookingTerminated
Grünenthal GmbHIndustry
NCT03530345 · 182 participants · Start May 30, 2018 · Primary completion Jul 31, 2019
Drug: Neridronic acid 100 mg; Placebo · For: Complex Regional Pain Syndrome (CRPS)
Sites: Huntsville, Alabama; Mobile, Alabama; Peoria, Arizona · 71 sites in all
- Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1Pivotal-lookingRecruiting
Ambros Therapeutics, Inc.Industry
NCT07857733 · 135 participants (planned) · Start Oct 13, 2026 · Primary completion Dec 31, 2028
Drug: Neridronate · For: Complex Regional Pain Syndrome Type I
Sites: Phoenix, Arizona
- Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TIPivotal-lookingCompleted
Ente Ospedaliero Ospedali GallieraAcademic, hospital or other
NCT01140321 · 120 participants · Start Jan 2004 · Primary completion May 2010
Drug: Neridronate · For: Osteoporosis; Thalassemia Major; Thalassemia Intermedia
Sites: Brindisi, Italy; Ferrara, Italy; Genova, Italy · 8 sites in all
- Efficacy Study of Neridronate to Treat Painful Osteoarthritis of the Knee With Bone Marrow Lesions.Status unknown
ASST Gaetano Pini-CTOAcademic, hospital or other
NCT01803360 · 60 participants (planned) · Start Mar 2013 · Primary completion Jul 2013
Drug: Neridronate · For: Osteoarthritis, Knee
Sites: Milan, Italy
Newest research
PubMed records naming it or its code names, newest first.
- Decoration of N-heterocyclic cores with bisphosphonates: synthetic access to mono- and di-substituted s-triazine linkers, and their structurally diverse coordination networks.
Chachlaki E, Choquesillo-Lazarte D, Demadis KD · Dalton Trans 2026
- Evidence-Based Therapeutic Methods for Reflex Sympathetic Dystrophy: A Systematic Review.
Bagwan H, Shinde S · Cureus 2026
- Acute Orbital Inflammation following Neridronate Therapy: A Case Report.
Ginelli S, Cattaneo J, Bruno A, et al. · Case Rep Ophthalmol 2026
- MRI Distribution of Foot Bone Marrow Edema of Presumed Algodystrophic/BMES-Like Origin: A Small Retrospective Case Series with 3-Month Clinical Follow-Up.
Messina F, D'Arrigo C, Bonifacio M, et al. · J Clin Med 2026
- Circulating Piezo 1 Levels in Complex Regional Pain Syndrome Type 1 and Their Association with Time from Neridronate Treatment.
Assirelli E, Ciaffi J, Naldi S, et al. · Biomedicines 2026
- Effectiveness and safety of neridronate in chronic nonbacterial osteomyelitis: insight from the CAMELOT registry.
Marino A, Amati A, Di Taranto R, et al. · Ther Adv Musculoskelet Dis 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.